KMT2D is a key regulator of transcriptional enhancer function and plays an important role in maintaining genomic stability [44], and it is mutated in a large number of different cancers (e.g., diffuse large B cell lymphoma, small cell undifferentiated lung cancer, and medulloblastoma) [45–47]. The gene discussed is KMT2D; the disease is medulloblastoma.